196 related articles for article (PubMed ID: 19608672)
1. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.
Giraldo P; Alfonso P; Atutxa K; Fernández-Galán MA; Barez A; Franco R; Alonso D; Martin A; Latre P; Pocovi M
Haematologica; 2009 Dec; 94(12):1771-5. PubMed ID: 19608672
[TBL] [Abstract][Full Text] [Related]
2. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
Giraldo P; Andrade-Campos M; Alfonso P; Irun P; Atutxa K; Acedo A; Barez A; Blanes M; Diaz-Morant V; Fernández-Galán MA; Franco R; Gil-Cortes C; Giner V; Ibañez A; Latre P; Loyola I; Luño E; Hernández-Martin R; Medrano-Engay B; Puerta J; Roig I; de la Serna J; Salamero O; Villalón L; Pocovi M
Blood Cells Mol Dis; 2018 Feb; 68():173-179. PubMed ID: 27836529
[TBL] [Abstract][Full Text] [Related]
3. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
[TBL] [Abstract][Full Text] [Related]
4. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Pastores GM; Barnett NL; Kolodny EH
Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
[TBL] [Abstract][Full Text] [Related]
5. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
Elstein D; Hollak C; Aerts JM; van Weely S; Maas M; Cox TM; Lachmann RH; Hrebicek M; Platt FM; Butters TD; Dwek RA; Zimran A
J Inherit Metab Dis; 2004; 27(6):757-66. PubMed ID: 15505381
[TBL] [Abstract][Full Text] [Related]
6. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
Serratrice C; Swiader L; Serratrice J
J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.
Cox TM; Amato D; Hollak CE; Luzy C; Silkey M; Giorgino R; Steiner RD;
Orphanet J Rare Dis; 2012 Dec; 7():102. PubMed ID: 23270487
[TBL] [Abstract][Full Text] [Related]
8. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
[TBL] [Abstract][Full Text] [Related]
9. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
Pastores GM; Elstein D; Hrebícek M; Zimran A
Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
[TBL] [Abstract][Full Text] [Related]
10. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
[TBL] [Abstract][Full Text] [Related]
11. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
Giraldo P; Latre P; Alfonso P; Acedo A; Alonso D; Barez A; Corrales A; Franco R; Roldan V; Serrano S; Pocovi M
Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
[TBL] [Abstract][Full Text] [Related]
12. Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution.
Machaczka M; Hast R; Dahlman I; Lerner R; Klimkowska M; Engvall M; Hägglund H
Ups J Med Sci; 2012 Mar; 117(1):28-34. PubMed ID: 22247978
[TBL] [Abstract][Full Text] [Related]
13. Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
Brand M; Muller A; Alsop J; van Schaik IN; Bembi B; Hughes D
Pharmacoepidemiol Drug Saf; 2015 Mar; 24(3):329-33. PubMed ID: 25656910
[TBL] [Abstract][Full Text] [Related]
14. Randomized, controlled trial of miglustat in Gaucher's disease type 3.
Schiffmann R; Fitzgibbon EJ; Harris C; DeVile C; Davies EH; Abel L; van Schaik IN; Benko W; Timmons M; Ries M; Vellodi A
Ann Neurol; 2008 Nov; 64(5):514-22. PubMed ID: 19067373
[TBL] [Abstract][Full Text] [Related]
15. Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction.
Elstein D; Guedalia J; Doniger GM; Simon ES; Antebi V; Arnon Y; Zimran A
Genet Med; 2005 Feb; 7(2):124-30. PubMed ID: 15714080
[TBL] [Abstract][Full Text] [Related]
16. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
Amato D; Patterson MA
J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
[TBL] [Abstract][Full Text] [Related]
17. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal disturbances and their management in miglustat-treated patients.
Belmatoug N; Burlina A; Giraldo P; Hendriksz CJ; Kuter DJ; Mengel E; Pastores GM
J Inherit Metab Dis; 2011 Oct; 34(5):991-1001. PubMed ID: 21779792
[TBL] [Abstract][Full Text] [Related]
19. Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study.
Kuter DJ; Mehta A; Hollak CE; Giraldo P; Hughes D; Belmatoug N; Brand M; Muller A; Schaaf B; Giorgino R; Zimran A
Blood Cells Mol Dis; 2013 Aug; 51(2):116-24. PubMed ID: 23683771
[TBL] [Abstract][Full Text] [Related]
20. Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment.
Shapiro BE; Pastores GM; Gianutsos J; Luzy C; Kolodny EH
Genet Med; 2009 Jun; 11(6):425-33. PubMed ID: 19346952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]